Furthermore, greater disease severity, whether measured for cognition or parkinsonism, was associated with lower levels of IL-1beta, IL-2 and IL-4, further supporting our finding that inflammatory markers decrease with disease progression. This evidence concerns the gene IL1B and Parkinson disease.